

Severity of SARS-CoV-2 Reinfections as Compared with

New England Journal of Medicine

385, 2487-2489

DOI: [10.1056/nejmc2108120](https://doi.org/10.1056/nejmc2108120)

Citation Report

#	ARTICLE	IF	CITATIONS
1	COVID-19 Vaccine Efficacy and the Evidence on Boosters. SSRN Electronic Journal, 0, , .	0.4	0
3	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. Nature Communications, 2022, 13, 532.	5.8	53
4	Omicron severity: milder but not mild. Lancet, The, 2022, 399, 412-413.	6.3	124
5	SARS-CoV-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity. SSRN Electronic Journal, 0, , .	0.4	3
6	Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet, The, 2022, 399, 437-446.	6.3	818
7	Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222. Clinical and Experimental Immunology, 2022, 208, 323-331.	1.1	3
9	Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. Diagnostic Microbiology and Infectious Disease, 2022, 103, 115659.	0.8	44
10	SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. Environmental Research, 2022, 209, 112911.	3.7	181
12	SARS-CoV-2 Reinfection Rate and Outcomes in Saudi Arabia: A National Retrospective Study. SSRN Electronic Journal, 0, , .	0.4	0
14	Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 Reinfections After a Second Wave With Predominance of Lambda in Lima and Callao, Peru. Open Forum Infectious Diseases, 2022, 9, .	0.4	2
16	Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. Nephrology Dialysis Transplantation, 2022, 37, 1400-1410.	0.4	21
18	Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. New England Journal of Medicine, 2022, 386, 1804-1816.	13.9	311
19	Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19. New England Journal of Medicine, 2022, 386, 1221-1229.	13.9	98
21	Reinfection in COVID-19: Do we exaggerate our worries?. European Journal of Clinical Investigation, 2022, 52, e13767.	1.7	11
22	Surfing Corona waves “ instead of breaking them: Rethinking the role of natural immunity in COVID-19 policy. F1000Research, 0, 11, 337.	0.8	0
23	Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infectious Diseases, The, 2022, 22, 791-801.	4.6	84
24	Real World Estimate of Vaccination Protection in Individuals Hospitalized for COVID-19. Vaccines, 2022, 10, 550.	2.1	4
25	Potential prophylactic efficacy of mast cell stabilizers against COVID-19 vaccine-induced anaphylaxis. Clinical and Molecular Allergy, 2021, 19, 25.	0.8	1

#	ARTICLE	IF	CITATIONS
28	Which vaccination strategy against COVID-19?. <i>International Health</i> , 2023, 15, 150-160.	0.8	0
30	Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. <i>The Lancet Global Health</i> , 2022, 10, e961-e969.	2.9	120
31	Clinical Characteristics and Outcomes of Patients With SARS-CoV-2 Reinfection. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2022, 6, 361-372.	1.2	4
32	COVID-19 in the 47 countries of the WHO African region: a modelling analysis of past trends and future patterns. <i>The Lancet Global Health</i> , 2022, 10, e1099-e1114.	2.9	58
33	Forecasting the Trajectory of the COVID-19 Pandemic under Plausible Variant and Intervention Scenarios: A Global Modelling Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
34	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
35	Clinical Time Delay Distributions of COVID-19 in 2020â€“2022 in the Republic of Korea: Inferences from a Nationwide Database Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3269.	1.0	10
36	A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge. <i>Nature Communications</i> , 2022, 13, .	5.8	22
37	Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia. <i>PLoS ONE</i> , 2022, 17, e0270801.	1.1	18
38	The Impact of the Highly Virulent SARS-CoV-2 Gamma Variant on Young Adults in the State of SÃ£o Paulo: Was It Inevitable?. <i>Cureus</i> , 2022, , .	0.2	3
40	Transient and durable T cell reactivity after COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	7
41	Reinfection, recontamination and revaccination for SARS-CoV-2. <i>World Journal of Methodology</i> , 2022, 12, 258-263.	1.1	0
42	SARS-CoV-2 Reinfection Rate and Outcomes in Saudi Arabia: A National Retrospective Study. <i>International Journal of Infectious Diseases</i> , 2022, 122, 758-766.	1.5	15
44	Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data. <i>Lancet Regional Health - Europe, The</i> , 2022, 20, 100452.	3.0	37
45	Risk and severity of SARS-CoV-2 reinfections during 2020â€“2022 in Vojvodina, Serbia: A population-level observational study. <i>Lancet Regional Health - Europe, The</i> , 2022, 20, 100453.	3.0	47
46	Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection. <i>JAMA Network Open</i> , 2022, 5, e2223917.	2.8	19
47	Post COVID-19 condition and its potential impact on disabilityâ€”A proposal for a calculation basis for the disability insurance sector. <i>Zeitschrift Fur Die Gesamte Versicherungswissenschaft</i> , 2022, 111, 191-208.	1.2	0
48	Association of periodontal therapy, with inflammatory biomarkers and complications in COVID-19 patients: a case control study. <i>Clinical Oral Investigations</i> , 2022, 26, 6721-6732.	1.4	12

#	ARTICLE	IF	CITATIONS
49	SARS-CoV-2 reinfection across a spectrum of immunological states. Health Science Reports, 2022, 5, .	0.6	1
50	Rapid Increase in Suspected SARS-CoV-2 Reinfections, Clark County, Nevada, USA, December 2021. Emerging Infectious Diseases, 2022, 28, 1977-1981.	2.0	8
51	Understanding the dynamic relation between wastewater SARS-CoV-2 signal and clinical metrics throughout the pandemic. Science of the Total Environment, 2022, 853, 158458.	3.9	19
52	COVID-19 Vaccine Effectiveness and the Evidence on Boosters: A Systematic Review (with Partial) Tj ETQq1 1 0.784314 rgBT ₂ /Overlo	0.4	
53	SARS-CoV-2 reinfections during the first three major COVID-19 waves in Bulgaria. PLoS ONE, 2022, 17, e0274509.	1.1	8
54	Duration of immune protection of SARS-CoV-2 natural infection against reinfection. Journal of Travel Medicine, 2022, 29, .	1.4	54
55	Comparative Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Variants in the Ferret Model. MBio, 2022, 13, .	1.8	10
56	COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 during Delta variant surge: a preliminary assessment from a case-control study in St. Petersburg, Russia. BMC Public Health, 2022, 22, .	1.2	4
57	Early Outpatient Treatment With Remdesivir in Patients at High Risk for Severe COVID-19: A Prospective Cohort Study. Open Forum Infectious Diseases, 2022, 9, .	0.4	19
58	Surfing Corona waves “ instead of breaking them: Rethinking the role of natural immunity in COVID-19 policy. F1000Research, 0, 11, 337.	0.8	0
59	Effect on the conformations of the spike protein of SARS-CoV-2 due to mutation. Biotechnology and Applied Biochemistry, 2023, 70, 979-991.	1.4	2
60	Risk and severity of SARS-CoV-2 reinfection among patients with multiple sclerosis vs. the general population: a population-based study. BMC Neurology, 2022, 22, .	0.8	4
61	Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England. JAMA Network Open, 2022, 5, e2238354.	2.8	43
62	The pharmaceutical industry is dangerous to health. Further proof with COVID-19. , 0, 13, 475.		2
63	Schools™s Out? Simulating Schooling Strategies During COVID-19. Lecture Notes in Computer Science, 2022, , 48-59.	1.0	1
64	Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. Lancet Microbe, The, 2022, 3, e944-e955.	3.4	34
65	Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nature Medicine, 2022, 28, 2398-2405.	15.2	241
66	Clinical characteristics and risks of the convalescent COVID-19 patients with re-detectable positive RNA test: a 430 patients with Omicron infected cross-sectional survey in Tianjin, China. Journal of Infection and Public Health, 2022, 15, 1409-1414.	1.9	1

#	ARTICLE	IF	CITATIONS
67	Smoking cessation in the elderly as a sign of susceptibility to symptomatic COVID-19 reinfection in the United States. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
68	Evolution of neutralizing antibodies and cross-activity against different variants of SARS-CoV-2 in patients recovering from COVID-19. <i>Journal of the Formosan Medical Association</i> , 2023, 122, 714-722.	0.8	4
69	Emergence of BA.4/BA.5 Omicron Sub-lineages and Increased SARS-CoV-2 Incidence in Senegal. <i>Coronaviruses</i> , 2022, 04, .	0.2	1
71	Clinical characteristics and risk factors for a prolonged length of stay of patients with asymptomatic and mild COVID-19 during the wave of Omicron from Shanghai, China. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	0
72	Prior immunization status of COVID-19 patients and disease severity: A multicenter retrospective cohort study assessing the different types of immunity. <i>Vaccine</i> , 2023, 41, 598-605.	1.7	0
76	Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors. <i>Viruses</i> , 2023, 15, 175.	1.5	33
77	COVID-19 host genetics and ABO blood group susceptibility. , 2023, 1, .		1
78	Maternal and perinatal outcomes following pre-Delta, Delta, and Omicron SARS-CoV-2 variants infection among unvaccinated pregnant women in France and Switzerland: a prospective cohort study using the COVI-PREG registry. <i>Lancet Regional Health - Europe</i> , The, 2023, 26, 100569.	3.0	18
79	Schools Out? Simulating Schooling Strategies During COVID-19. <i>Lecture Notes in Computer Science</i> , 2023, , 95-106.	1.0	1
82	The different epidemiological questions on SARS-CoV-2 reinfections. <i>International Journal of Epidemiology</i> , 0, , .	0.9	0
86	Severity and Outcomes of SARS-CoV-2 Reinfection Compared with Primary Infection: A Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 3335.	1.2	23
87	Effectiveness and Protection Duration of Anti-COVID-19 Vaccinations among Healthcare Personnel in Cluj-Napoca, Romania. <i>Vaccines</i> , 2023, 11, 521.	2.1	1
88	Asymptomatic COVID-19 Reinfection in a Pediatric Patient with Heterotaxy Syndrome. <i>Viral Immunology</i> , 2023, 36, 144-148.	0.6	0
89	Resolving the enigma of Iquitos and Manaus: A modeling analysis of multiple COVID-19 epidemic waves in two Amazonian cities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	7
90	Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2. <i>American Journal of Epidemiology</i> , 0, , .	1.6	1
92	Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity. <i>Vaccines</i> , 2023, 11, 655.	2.1	3
93	Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	7
94	SARS-CoV-2 Reinfection and Severity of the Disease: A Systematic Review and Meta-Analysis. <i>Viruses</i> , 2023, 15, 967.	1.5	13

#	ARTICLE	IF	CITATIONS
125	Clinical course and management of COVID-19 in the era of widespread population immunity. Nature Reviews Microbiology, 2024, 22, 75-88.	13.6	1